Monday's Health Winners & Losers
Health indices lacked luster Monday, while a few biotech stocks kicked off the week with a swath of regulatory news.
GlaxoSmithKline (GSK) said Monday that the Food and Drug Administration has more questions for the company regarding its cervical cancer vaccine Cervarix before the product can be approved.
The agency's Center for Biologics Evaluation and Research issued Glaxo a "complete response letter" to its Cervarix application, signaling that the review is complete but questions have to be answered before the drug can be approved. Glaxo said it will submit a response to the FDA letter on Cervarix, which is already approved in markets outside the U.S., as soon as possible.
Glaxo shares fell $1.05, or 2%, to $51.95. The stock is a component of the Amex pharmaceutical index, which was down 3.57, or 1%, to 344.25.Meanwhile, the European Commission granted marketing authorization for Atripla, an HIV drug that was joint-filed by Bristol-Myers Squibb (BMY), Genentech (DNA) and Merck (MRK) for commercialization in the 27 countries of the E.U., as well as in Norway and Iceland. The drug has been approved in the U.S. since 2006. Bristol was up just 3 cents at $28.11, Genentech was down $1.32, or 2%, at $67.11, and Merck was up 8 cents, or 0.1%, to $59.65. In other regulatory news, Medtronic (MDT) said Monday that it received Japanese regulatory approval on Dec. 10 for its Sprint Quattro lead, a wire used with implantable cardioverter-defibrillators (ICDs) that detect and treat rapid and potentially lethal heart rhythms. The company said it hopes to receive reimbursement for the lead by Jan. 1, in which case it would immediately begin the commercial launch in Japan. In October, the company recalled its Fidelis leads, sparking a shift to the use of its Quattro leads, but Quattro lead product hadn't been approved in Japan. Medtronic shares were down 25 cents, or 0.5%, at $49.15.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV